1. Home
  2. INTT vs MGNX Comparison

INTT vs MGNX Comparison

Compare INTT & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo inTest Corporation

INTT

inTest Corporation

HOLD

Current Price

$14.15

Market Cap

123.8M

Sector

Technology

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$3.04

Market Cap

115.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INTT
MGNX
Founded
1981
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
123.8M
115.8M
IPO Year
1997
2013

Fundamental Metrics

Financial Performance
Metric
INTT
MGNX
Price
$14.15
$3.04
Analyst Decision
Strong Buy
Hold
Analyst Count
3
5
Target Price
$14.00
$3.40
AVG Volume (30 Days)
135.1K
1.3M
Earning Date
06-02-2026
06-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$66,801,000.00
$149,500,000.00
Revenue This Year
$13.07
N/A
Revenue Next Year
$6.52
N/A
P/E Ratio
N/A
N/A
Revenue Growth
66.06
N/A
52 Week Low
$5.24
$0.99
52 Week High
$15.01
$3.50

Technical Indicators

Market Signals
Indicator
INTT
MGNX
Relative Strength Index (RSI) 72.36 72.48
Support Level $7.21 $1.45
Resistance Level $15.01 $3.50
Average True Range (ATR) 0.96 0.22
MACD 0.09 0.08
Stochastic Oscillator 83.07 74.26

Price Performance

Historical Comparison
INTT
MGNX

About INTT inTest Corporation

inTest Corp is a supplier of test and process solutions for use in manufacturing and testing across a range of markets including automotive, defense/aerospace, industrial, medical, semiconductor and telecommunications. The company manages its business as three operating segments which is also their reporting units that includes Electronic Test, Environmental Technologies and Process Technologies. Electronic Test (which includes semiconductor test equipment, flying probe and in-circuit testers), Environmental Technologies (which includes its thermal test, process and storage products) and Process Technologies (which includes induction heating and video imaging products). The company operates their business and sells its products both domestically and internationally.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: